Drug Trial Radar · NCT07636564
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Apr 16, 2031
Study completion Apr 16, 2032
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well adding revumenib to usual treatment (blinatumomab) compared to usual treatment alone works in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) or acute leukemia with ambiguous lineage (ALAL) with KMT2A-translocation. Revumenib binds to a protein called menin and keeps it from binding to another protein called KMT2A. This stops or slows the growth of leukemia cells with changes in the KMT2A gene. Blinatumomab binds to CD19, which is found on most B cells (a type of white blood cell) and some types of leukemia cells. It also binds to a protein called CD3, which is found on T cells (another type of white blood cell). This may help the immune system kill cancer cells. In addition to blinatumomab, usual treatment also includes dexamethasone, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, calaspargase pegol, doxorubicin, thioguanine, daunorubicin, vincristine and leucovorin. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Chemotherapy drugs, such as cytarabine, mercaptopurine, calaspargase pegol, doxorubicin, thioguanine, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Leucovorin is also being studied in the treatment of cancer. It is a type of chemoprotective agent and a type of chemosensitizing agent. Adding revumenib to usual treatment with blinatumomab may be safe, tolerable and more effective than blinatumomab alone in lowering the amount of leukemia in patients with B-ALL or ALAL with the KMT2A translocation.
Conditions
- Acute Leukemia of Ambiguous Lineage
- B Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- T Acute Lymphoblastic Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo CSF and blood sample collection
BlinatumomabBiological
Given IV
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy and aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and aspiration
Calaspargase PegolDrug
Given IV
Chest RadiographyProcedure
Undergo chest x-ray
Computed TomographyProcedure
Undergo CT or PET/CT
CyclophosphamideDrug
Given IV
CytarabineDrug
Given IV or SC
Daunorubicin HydrochlorideDrug
Given IV
DexamethasoneDrug
Given PO or IV
DoxorubicinDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
Leucovorin CalciumDrug
Given PO or IV
MercaptopurineDrug
Given PO
MethotrexateDrug
Given IT or IV
Multigated Acquisition ScanProcedure
Undergo MUGA
Positron Emission TomographyProcedure
Undergo PET/CT
RevumenibDrug
Given PO
ThioguanineDrug
Given PO
VincristineDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (Safety run-in: Cohort A)Time frame: During cycle 1 (cycle 1 length = 28 days)
- Measurable residual disease (MRD) negativity rate (Cohort A)Time frame: Up to 35 days after start of therapy
- MRD-event-free survival (EFS) (Cohort A)Time frame: From date of randomization and up to 10 years
- Incidence of toxicities of interest (TOI) (Cohort B)Time frame: Up to 30 days after last dose of study treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.